1,438 Shares in ResMed Inc. (NYSE:RMD) Acquired by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC acquired a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,438 shares of the medical equipment provider's stock, valued at approximately $340,000.

Other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC raised its position in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of ResMed during the third quarter worth $34,000. Rosenberg Matthew Hamilton bought a new stake in shares of ResMed during the fourth quarter worth $54,000. Capital Performance Advisors LLP bought a new stake in shares of ResMed during the third quarter worth $60,000. Finally, Venturi Wealth Management LLC raised its position in shares of ResMed by 55.7% during the third quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider's stock worth $83,000 after acquiring an additional 122 shares during the last quarter. Institutional investors own 54.98% of the company's stock.

ResMed Trading Down 0.1 %

NYSE:RMD traded down $0.34 on Friday, reaching $236.84. The company's stock had a trading volume of 830,561 shares, compared to its average volume of 1,059,213. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The firm has a market cap of $34.78 billion, a PE ratio of 27.96, a PEG ratio of 1.57 and a beta of 0.70. The business's 50-day moving average price is $239.18 and its two-hundred day moving average price is $237.39. ResMed Inc. has a 1-year low of $170.56 and a 1-year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Equities research analysts anticipate that ResMed Inc. will post 9.44 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. ResMed's dividend payout ratio is currently 25.03%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They set a "buy" rating for the company. Robert W. Baird lifted their price objective on ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research note on Friday, January 31st. Royal Bank of Canada lifted their price objective on ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research note on Friday, October 25th. Finally, KeyCorp lifted their price objective on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $244.73.

Insider Transactions at ResMed

In related news, Director Witte Jan De sold 796 shares of the company's stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the sale, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Justin Leong sold 6,160 shares of the company's stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the sale, the insider now owns 21,718 shares in the company, valued at $5,279,428.62. This represents a 22.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,094 shares of company stock valued at $2,704,941 over the last three months. Company insiders own 0.71% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.